Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
29-30 March, 2025
Not Confirmed
Not Confirmed
31 March-01 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
29-30 March, 2025
Industry Trade Show
Not Confirmed
31 March-01 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
27 Mar 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250326688177/en/Celltrions-Remdantry-previously-known-as-Inflectra-will-be-available-in-Canada-as-of-April-1-2025
12 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/steqeyma-ustekinumab-stba-a-biosimilar-to-stelara-ustekinumab-now-available-in-the-united-states-302399685.html
11 Mar 2025
// BUSINESSWIRE
10 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-approves-celltrions-omlyclo-omalizumab-igec-as-the-first-and-only-biosimilar-with-interchangeability-designation-referencing-xolair-302396468.html
09 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-approves-celltrions-omlyclo-omalizumab-igec-as-the-first-and-only-biosimilar-with-interchangeability-designation-referencing-xolair-302396468.html
04 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/celltrion-receives-us-fda-approval-for-stoboclo-denosumab-bmwo-and-osenvelt-denosumab-bmwo-biosimilars-referencing-prolia-and-xgeva-302390957.html
ABOUT THIS PAGE
Celltrion is a supplier offers 2 products (APIs, Excipients or Intermediates).
Find a price of Infliximab bulk with JDMF offered by Celltrion
Find a price of Trastuzumab bulk with JDMF offered by Celltrion